CAP2 and ovarian carcinoma: CAP2 was upregulated in leukemia, gastric, breast, kidney, and liver cancer, whereas decreased in the bladder, brain, lung, prostate, oesophagus, and ovarian cancer, as well as sarcoma and melanoma (Figure 5A, Supplementary Figures 5–7).